{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:01:47Z","timestamp":1773745307849,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Alliance of Associations in Rheumatology","award":["CLI122"],"award-info":[{"award-number":["CLI122"]}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1136\/annrheumdis-2021-221366","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T04:31:39Z","timestamp":1633840299000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-5640","authenticated-orcid":false,"given":"Alessia","family":"Alunno","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6008-503X","authenticated-orcid":false,"given":"Aur\u00e9lie","family":"Najm","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-7972","authenticated-orcid":false,"given":"Pedro M","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd-R\u00fcdiger R","family":"Burmester","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-5136","authenticated-orcid":false,"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[]},{"given":"Gabriele","family":"De Marco","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6103-7056","authenticated-orcid":false,"given":"John D","family":"Isaacs","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-5763","authenticated-orcid":false,"given":"Isabelle","family":"Kon\u00e9-Paut","sequence":"additional","affiliation":[]},{"given":"C\u00e9sar","family":"Magro-Checa","sequence":"additional","affiliation":[]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3394-1451","authenticated-orcid":false,"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-6439","authenticated-orcid":false,"given":"Luca","family":"Quartuccio","sequence":"additional","affiliation":[]},{"given":"A V","family":"Ramanan","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[]},{"given":"Javier","family":"Rodr\u00edguez Carrio","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3073-7284","authenticated-orcid":false,"given":"Tanja A","family":"Stamm","sequence":"additional","affiliation":[]},{"given":"Sander W","family":"Tas","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-7336","authenticated-orcid":false,"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[]},{"given":"Dennis G","family":"McGonagle","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-5417","authenticated-orcid":false,"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2021-221366_bib1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/annrheumdis-2020-219724","article-title":"EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19","volume":"80","author":"Alunno","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221366_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2014-206350","article-title":"2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations","volume":"74","author":"van der Heijde","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221366_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/22221751.2021.1898291","article-title":"Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic","volume":"10","author":"To","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"10.1136\/annrheumdis-2021-221366_bib6","article-title":"Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider","volume":"80","author":"Alunno","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221366_bib7","article-title":"Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: a randomised controlled trial","volume":"11","author":"Dabbous","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/annrheumdis-2021-221366_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/20477724.2021.1890887","article-title":"Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection","volume":"115","author":"Galan","year":"2021","journal-title":"Pathog Glob Health"},{"key":"10.1136\/annrheumdis-2021-221366_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.05.020","article-title":"An open-label randomized controlled trial of the effect of lopinavir\/ritonavir, lopinavir\/ritonavir plus IFN-\u03b2-1a and hydroxychloroquine in hospitalized patients with COVID-19","author":"Ader","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1136\/annrheumdis-2021-221366_bib10","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1513\/AnnalsATS.202008-940OC","article-title":"Hydroxychloroquine versus azithromycin for hospitalized patients with COVID-19. Results of a randomized, active comparator trial","volume":"18","author":"Brown","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1136\/annrheumdis-2021-221366_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the together randomized clinical trial","volume":"4","author":"Reis","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1136\/annrheumdis-2021-221366_bib12","article-title":"Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial","author":"Sivapalan","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1136\/annrheumdis-2021-221366_bib13","doi-asserted-by":"crossref","first-page":"E693","DOI":"10.9778\/cmajo.20210069","article-title":"Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial","volume":"9","author":"Schwartz","year":"2021","journal-title":"CMAJ Open"},{"key":"10.1136\/annrheumdis-2021-221366_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88509-9","article-title":"An open-label randomized controlled trial evaluating the efficacy of chloroquine\/hydroxychloroquine in severe COVID-19 patients","volume":"11","author":"R\u00e9a-Neto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1136\/annrheumdis-2021-221366_bib15","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/0885066621994057","article-title":"A comparison of methylprednisolone and dexamethasone in intensive care patients with COVID-19","volume":"36","author":"Ko","year":"2021","journal-title":"J Intensive Care Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","author":"Rosas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","article-title":"Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"9","author":"Soin","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib18","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib19","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (recovery): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2021-221366_bib20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamainternmed.2021.2209","article-title":"Effectiveness of tocilizumab in patients hospitalized with COVID-19: a follow-up of the CORIMUNO-TOCI-1 randomized clinical trial","volume":"181","author":"Mariette","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","author":"Shankar-Hari","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2021-221366_bib22","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","author":"Tharaux","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib24","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2021-221366_bib26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001455","article-title":"Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial","volume":"7","author":"Lopes","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/annrheumdis-2021-221366_bib28","author":"Horby"},{"key":"10.1136\/annrheumdis-2021-221366_bib29","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib31","first-page":"00331","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (cov-barrier): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib33","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (recovery): a randomised controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2021-221366_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/annrheumdis-2021-221366_bib35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib36","author":"Dougan"},{"key":"10.1136\/annrheumdis-2021-221366_bib37","article-title":"A neutralizing monoclonal antibody for hospitalized patients with Covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221366_bib38","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijid.2021.03.015","article-title":"Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: a phase II, randomized, controlled, open-label study","volume":"105","author":"Pandit","year":"2021","journal-title":"Int J Infect Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724203988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724203988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2021-221366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T01:22:24Z","timestamp":1737249744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724203988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0003496724203988"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2021-221366","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2021-221366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}